The Worldwide Alzheimer's Disease Neuroimaging Initiative: ADNI-3 updates and global perspectives

C.J. Weber, M.C. Carrillo, W. Jagust, C.R. Jack, L.M. Shaw, J.Q. Trojanowski, A.J. Saykin, L.A. Beckett, C. Sur, N.P. Rao, P.C. Mendez, S.E. Black, K. Li, T. Iwatsubo, Chia-Chen Chang, A.L. Sosa, C.C. Rowe, R.J. Perrin, J.C. Morris, A.M.B. HealanS.E. Hall, M.W. Weiner

Research output: Contribution to journalJournal Article peer-review

33 Scopus citations

Abstract

The Worldwide Alzheimer's Disease Neuroimaging Initiative (WW-ADNI) is a collaborative effort to investigate imaging and biofluid markers that can inform Alzheimer's disease treatment trials. It is a public-private partnership that spans North America, Argentina, Australia, Canada, China, Japan, Korea, Mexico, and Taiwan. In 2004, ADNI researchers began a naturalistic, longitudinal study that continues today around the globe. Through several successive phases (ADNI-1, ADNI-GO, ADNI-2, and ADNI-3), the study has fueled amyloid and tau phenotyping and refined neuroimaging methodologies. WW-ADNI researchers have successfully standardized analyses and openly share data without embargo, providing a rich data set for other investigators. On August 26, 2020, the Alzheimer's Association convened WW-ADNI researchers who shared updates from ADNI-3 and their vision for ADNI-4.
Original languageAmerican English
JournalAlzheimer's and Dementia: Translational Research and Clinical Interventions
Volume7
Issue number1
DOIs
StatePublished - 2021

Keywords

  • Alzheimer's disease
  • Alzheimer's disease
  • MRI
  • MRI
  • PET
  • PET
  • Tau
  • Tau
  • amyloid
  • amyloid
  • biomarkers
  • biomarkers
  • cerebrospinal fluid
  • cerebrospinal fluid
  • cognitive impairment
  • cognitive impairment
  • neuroimaging
  • neuroimaging

Fingerprint

Dive into the research topics of 'The Worldwide Alzheimer's Disease Neuroimaging Initiative: ADNI-3 updates and global perspectives'. Together they form a unique fingerprint.

Cite this